A pproximately 1000 years ago, a Persian (Iranian) physician by the name of Abu-'Ali al-Husayn ibn Abdallah ibn-Sina (commonly known as "Ibn Sina," but also known as "Avicenna" in the West), wrote a treatise on the testing of drugs. This work, which was a chapter in his much larger The Canon of Medicine, was titled "The recognition of the strengths of the characteristics of medicines through experimentation" (1) . The title alone is astounding, considering that the era of formal experimentation with drugs is believed to have occurred 750 years later, with James Lind's famous experiment on scurvy with lime juice (2) . While the introduction and adaptation of new techniques in the design of clinical trials occurred after Lind, these developments were largely sporadic and took several centuries to advance. An important milestone was Gavarret's comprehensive work on the statistical analysis of clinical trials that was published in 1840 (3) . However, clinical trials as we know them today were largely a 20th-century phenomenon; thus, it is surprising to find echoes of many modern concepts in a work from a millennium ago.
Although one can envision that medical knowledge gradually advanced through the millennia via trial and error, there does not seem to be any evidence of the systematic testing of drugs before Ibn Sina's time. In an article focusing on the history of clinical trials (4), Bull notes, with regard to Greek medicine, that although the "natural sequel in therapeutics would seem to be the clinical trial . . . the Hippocratic writers with their confidence in general philosophy did not draw this conclusion." Regarding Roman medicine, he continues, "Dioscorides wrote the earliest scientific account of medical botany . . . but he did not describe the methods of testing therapeutic action."
Despite this, several examples of simple toxicology experiments have been documented. In each of the following examples, different drugs were given before or after administration of the poison and mortality was the measured outcome or end point, but other crucial details about these experiments remain unknown. Mithridates VI (132-63 BCE), a Persian king who ruled over Pontus (present-day Turkey), tested various poisons and their antidotes on convicts (5-7). Pliny the Elder states that after Mithridates' death, Pompeius Lenaeus translated Mithridates' handwritten texts regarding his experiments into Latin at the request of Pompey the Great (8) . However, there is scant mention of Mithridates' works by later Roman and Greek writers, with the exception of Galen (6, 7, 9 -12) . Mithridates' work appears not to have survived into modern times, and thus his experimental methods remain unknown (7). Likewise, Attalus III (170 -133 BCE) and Galen (131-201 CE) respectively tested at least 1 poison and its antidote on convicts and birds, but again, the details of these experiments are unknown (5-7).
The description of a control group is perhaps the earliest known example of a concept associated with modern clinical trials. Approximately 1 century before Ibn Sina, a work by Razi (a Persian physician also known as "Rhazes," 865-925 CE) titled Hawi, described the dividing of a group of patients with meningitis into an intervention group (bloodletting) versus control (no bloodletting) to determine the efficacy of this practice (13) . Although Razi's observation predates Lind by approximately 850 years and is important in its own right, the scope of what Ibn Sina would next propose was greater and more comprehensive than anything before or for many centuries thereafter. This article takes a closer look at Ibn Sina's life accomplishments and the first known treatise on clinical trials. (For the exact methods and sources used for our translation of this treatise and other parts of Ibn Sina's The Canon of Medicine, please refer to the Note at the end of the article).
IBN SINA'S BIOGRAPHY
Ibn Sina was born in 980 CE in the village of Afshona (present-day Uzbekistan) during the dying days of the Samanid dynasty (14 -16) . The Samanid dynasty is noteworthy in that it was among the first indigenous Persian political entities to arise after the defeat and dissolution of the Persian Empire at the hands of Arab Muslims. In fact, as Ibn Sina was beginning the decades-long task of compiling The Canon of Medicine, the poet Ferdowsi was completing another classic that was decades in the making: the epic Shahnameh. It should be noted that Razi was also a product of the Samanid era. Ibn Sina was thus born into a period that was marked by the political, cultural, linguistic, and scientific reawakening of Persia (15) (16) (17) .
Ibn Sina was still a child when his family moved to Bukhara (present-day Uzbekistan), the capital of the Samanid dynasty and one of the world's leading intellectual centers (14 -16) . Ibn Sina's father, a Samanid governor, ensured that his son was well tutored. Ibn Sina was precocious, and according to his autobiography, he had memorized the Koran by age 10 (14 -16). By age 18, having studied under the famous philosopher Natili, he was well versed in Greek philosophy and Islamic theology and had become a practicing physician (14 -16) .
Although Ibn Sina would take an interest and excel in many fields, the bulk of his life's work comprised philosophy, theology, and medicine. After the fall of the Samanid dynasty in 999 CE, Ibn Sina went from city to city, fleeing persecution and seeking benefactors to support his endeavors, at times finding himself a high-ranking vizier, at other times finding himself a prisoner (14 -16) . He started his journey in Gorgan (where he began writing The Canon of Medicine), and over the next 3 decades, he traveled through Isfahan, Rey, and other cities located in present-day Iran until his death from a recurring abdominal ailment in 1037 CE (14 -16) . He died in Hamadan, where a mausoleum still stands in his honor.
IBN SINA THE PHYSICIAN
The Canon of Medicine, Ibn Sina's most famous work, took over 20 years to write and was a synthesis of Aristotelian, Galenic, Arabian, Persian, and Indian medicine. In Europe, it was the main textbook (translated into Latin) in many medical schools between the 14th and 16th centuries. It was taught as late as the 19th century in some areas of Europe (14 -16) .
In the beginning of this encyclopedic work, Ibn Sina elegantly states, "Medicine is a science by which we learn about the conditions of the human body. Its purpose is to preserve health when well and restore health when ill." The book is divided into 5 volumes and contains approximately 1 million words (18) . The first volume is a compendium of medical principles, the second is a reference for individual drugs, the third contains organ-specific diseases, the fourth discusses systemic illnesses as well as a section of preventive health measures, and the fifth contains descriptions of compound medicines. With entire chapters devoted to exercise, preventive medicine, and travel medicine, this work was both comprehensive and prescient. Ibn Sina is credited with many varied medical observations and discoveries, such as recognizing the potential of airborne transmission of disease, providing insight into many psychiatric conditions, recommending use of forceps in deliveries complicated by fetal distress, distinguishing mediastinitis from pleurisy, distinguishing central from peripheral facial paralysis, and describing guinea worm infection and trigeminal neuralgia (1, 19 -24) .
IBN SINA'S TREATISE ON DRUG TESTING
In Ibn Sina's time, the principles underlying diseases and their treatment included the "humoral theory" and "temperaments." Although the humoral theory dates back to the Greeks, it had transformed and acquired new components through the intervening centuries and with the influence of Galenic medicine. The 4 humors, or substances, found in the body were blood, black bile, yellow bile, and phlegm, and their different states (hot, cold, moist, dry) were called "temperaments" (14) . Each patient's specific organ and disease were considered to have a certain overall temperament based on the humors and their temperaments, and each specific treatment also had its own temperament. The physician was thus tasked with finding
Key Summary Points
Although the era of formal experimentation with drugs is thought to have begun with James Lind in the 18th century, there is evidence of human trials before that. The ancient Greeks, Romans, and Persians carried out experiments with poisons and antidotes. In the 10th century, a Persian physician by the name of Razi described the firstknown use of a control group in a human trial.
Ibn Sina, an 11th-century Persian physician, wrote the earliest known treatise relating to clinical trials. Ibn Sina's The Canon of Medicine was a synthesis of Aristotelian, Galenic, Arabian, Persian, and Indian medicine. This was the main textbook in many European medical schools from the 14th to 16th centuries.
In a chapter in The Canon of Medicine, Ibn Sina describes 7 conditions for "the recognition of the strengths of the characteristics of medicines through experimentation." The therapeutic principles that are presented in his treatise are similar to concepts that define the modern clinical trial.
The 7 conditions are ensuring the use of pure drugs, testing of the drug for only 1 disease, the use of control groups, the use of dose escalation, the requirement of long-term observation, the requirement of reproducible results, and the requirement of human over animal testing.
Although the scientific method had yet to be formally described, Ibn Sina's treatise contained all of its components. However, the ultimate influence of his treatise on the progress of experimental design is questionable.
History of Medicine
Ibn Sina and the Clinical Trial www.annals.orgthe right balance, and it is in this setting that Ibn Sina presented his treatise on drug testing.
In the second volume of The Canon of Medicine, there is a chapter titled "The recognition of the strengths of the characteristics of medicines through experimentation." In this chapter, Ibn Sina states, "Experimentation will bring us complete understanding of the strength of drugs; however, only if the conditions below are followed." "1. The drug under question must be pure, not having been adversely affected by heat or cold; foreign substances must not have changed its essence; foreign substances have not added impurities to that drug. . . ."
Here, Ibn Sina clearly stresses the purity and proper storage of drugs, implying that the lack of an observed effect could be due to these factors. In a separate section of the second volume, he devotes a chapter to elaborate on this point. He notes that the properties of a given drug can be enhanced, weakened, or altered by boiling, burning, freezing, washing, grinding, storing in proximity to other drugs, and mixing or coadministering with other drugs (1).
"2.
The drug must only be tested for one condition, for if a patient has more than one condition, and each is in need of a different treatment, and the treatments are antagonistic, and if the patient recovers, we are left uncertain as to which of the conditions the drug was useful for."
In this and the previous statement, Ibn Sina gives clear consideration to confounding factors in the design of an experiment. By making the stipulation that the patient must have only 1 condition, he is giving us the equivalent of modern inclusion and exclusion criteria (in this case, the inclusion criterion would be a person with the disease of interest, disease X, and the exclusion criterion would be disease Y). "3. Drugs must be tested in contradictory disease states, and if they are beneficial in both, then it cannot be said that the actions of the drug is beneficial against a certain disease state."
This statement stresses testing drugs in different disease states. A "disease state" refers to a specific medical condition that is made up of particular humors and temperaments. Whereas Razi proposes a control group, Ibn Sina proposes testing a single drug in different populations (disease states) to ascertain its efficacy. Although less obvious than Razi's example, this nonetheless points to the use of control groups. Of note, the example Ibn Sina gives is not the intuitive and easy one (different results in different diseases). Rather, he states that even if the same treatment is beneficial in different diseases, drawing a conclusion can be difficult.
"4. The strength of the drug must be proportionate to the severity of the diseases . . . in these instances it is better to test the drug in low quantities, and test it in increasing quantities to determine its effect and to prevent untoward effects."
In this statement, Ibn Sina proposes dose escalation, emphasizing both therapeutic and adverse effects, which are the focus of modern phase I and phase II studies.
"5. The time at which the medicine's therapeutic effect becomes apparent must be considered. If the drug immediately works, it is clear that this effect is from the drug and the drug has a positive effect on its own. However, if the effect is delayed, and its therapeutic effect becomes apparent later, or if it shows an effect after the first application and then acts in the opposite way, then we will have difficulty in knowing the true strength of the drug."
This passage points to the importance of long-term observation. Ibn Sina emphasizes that sometimes a drug's effect is immediately recognized, whereas in other instances, it may take time before the effects can be ascertained (or that they may be confounded and not recognized). Thus, Ibn Sina states that the time to action, confounders, and the length of time of the observation must be considered during experimentation. These are the same considerations that go into the design of modern trials that seek to determine a drug's activity (efficacy and side effects). An extension of the modern drug trial, following the same logic and emphasis on long-term observation, has further developed into the practice of postmarketing surveillance.
"6. The drug must be observed for its continued action or for a prolonged period of time, for if its effect is real, then it will be seen continuously or in many instances. . . ."
In this point, Ibn Sina emphasizes the reproducibility of the finding, stating that for its effect to be considered valid, it must be demonstrated consistently. "7. In order to understand the strength and effect of a drug, it must first be tested in a human and then the judgment be made. Often it is possible that a drug is tested in a nonhuman and gives a result, whereas in the human body it will give a contrary result . . . for example, the Indian aconite plant (Aconitum ferox), which is a lethal poison to humans, has no effect on the starling."
In this passage, Ibn Sina not only shows a familiarity with testing of drugs in animals, he correctly concludes that ultimately the drugs need to be tested in humans. His understanding of this concept is astute, considering that as late as 1865, Claude Bernard, the great experimentalist and expounder of the scientific method, erroneously wrote, "Experiments on animals, with deleterious substances or in harmful circumstances, are very useful and entirely conclusive for the toxicology and hygiene of man" (25) .
Ibn Sina concludes this section with the following: "The above rules need to be considered to determine the strengths of medicines through experimentation."
The scientific method has been defined as a "systematic, empirical, controlled, and critical examination of hypothetical propositions about the associations among natural phenomena" (26) . In Ibn Sina's treatise, we find the foundations of a "systematic" approach in the comprehensive view and logic he brings to drug testing; the "empiriHistory of Medicine Ibn Sina and the Clinical Trial cal" component in the emphasis on direct observation in various circumstances; the "controlled" component in the recommendations for drug quality, testing in different groups, and recognition of confounders; and the "critical" component in the emphasis on reproducibility. Although the scientific method had yet to be formally described, Ibn Sina was able to approach this concept on his own, using the foundations of Greek logic.
Although Ibn Sina wrote the first treatise on drug testing, its influence on the progress of experimental design is questionable. As noted, The Canon of Medicine was one of the main textbooks of medicine in Europe for several centuries; however, we are unaware of any experimenters having referenced the treatise. At least 1 Latin translation of The Canon of Medicine contains this treatise (27) , so lack of translation is not a likely explanation. One possibility is that this relatively small section of the much larger work was overlooked or underemphasized by the physicians of that time. Regarding the latter, there are no records of Ibn Sina's case histories; thus, it is unknown whether these included any experiments related to his treatise. Ibn Sina had intended to publish his case histories along with The Canon of Medicine but they were lost before publishing (28) . Another possibility for the seeming lack of influence of this work on experimental design of drug testing is that this area has not been researched thoroughly. For example, it would be interesting to know whether Lind studied The Canon of Medicine (or if it was taught) while he was in Edinburgh, United Kingdom. This line of research warrants further study.
CONCLUSION
To the modern eye, the therapeutic principles set forth in Ibn Sina's treatise may appear to be self-evident, or perhaps even clumsily presented. Indeed, one can read The Canon of Medicine and refute most of its findings today. Furthermore, Ibn Sina's catalogue and classification of drugs is completely outdated (although there are still practitioners of his method today, and to be fair, his proposed treatments have never been rigorously tested). However, the most critical aspect of the treatise is that Ibn Sina proposed applying the principles of the scientific method to the testing of drugs. This, quite simply, is the basis of the modern clinical trial. Note: The University of Tehran Bulaq edition (reference 1) was used for the translated portions relating to The Canon of Medicine that appear in quotes. For the treatise on drug testing, we included the text directly relating to the general descriptions and principles of the 7 conditions that Ibn Sina described. We omitted some text that referred to specific examples of drugs and disease conditions. To verify the accuracy of our translation, we cross-checked the entire treatise with another version, dated 1592 (Rome edition in Arabic), located in the Saab Library at the American University in Beirut (http://ddc.aub.edu.lb/projects/saab/avicenna), for which we are grateful to Najwa Al-amin.
